Opthea in trading halt ahead of trial update

Latest News

Opthea (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, is scheduled to update investors tomorrow on the ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).

The company has entered a trading halt in anticipation of the highly-anticipated update.

The clinical trial is evaluating the safety and efficacy of Opthea's OPT-302 in combination with Novartis' PBS-listed LUCENTIS (ranibizumab) for wet AMD.

OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak - processes which contribute to the pathophysiology of retinal diseases